ID   PTN22_HUMAN             Reviewed;         807 AA.
AC   Q9Y2R2; A0N0K6; B1ALC8; D4NZ71; E9PLD8; E9PPI1; O95063; O95064;
AC   Q6IPX8; Q8WVM1;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 2.
DT   10-MAY-2017, entry version 155.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 22;
DE            EC=3.1.3.48 {ECO:0000269|PubMed:21719704};
DE   AltName: Full=Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP;
DE   AltName: Full=Lymphoid phosphatase;
DE            Short=LyP;
DE   AltName: Full=PEST-domain phosphatase;
DE            Short=PEP;
GN   Name=PTPN22; Synonyms=PTPN8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND INTERACTION WITH
RP   CBL.
RX   PubMed=10068674;
RA   Cohen S., Dadi H., Shaoul E., Sharfe N., Roifman C.M.;
RT   "Cloning and characterization of a lymphoid-specific, inducible human
RT   protein tyrosine phosphatase, Lyp.";
RL   Blood 93:2013-2024(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND VARIANT TRP-620.
RX   PubMed=21044313; DOI=10.1186/1471-2199-11-78;
RA   Wang S., Dong H., Han J., Ho W.T., Fu X., Zhao Z.J.;
RT   "Identification of a variant form of tyrosine phosphatase LYP.";
RL   BMC Mol. Biol. 11:78-78(2010).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TRP-620.
RA   Liu T., Zhang J., Fu G., Zhang Q., Ye M., Zhou J., Wu J., Shen Y.,
RA   Yu M., Chen S., Mao M., Chen Z.;
RT   "Human protein tyrosine phosphatase (70zpep) homolog.";
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-620.
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-620.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=16461343; DOI=10.1074/jbc.M600498200;
RA   Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J.,
RA   Jeffery D., Mortara K., Sampang J., Williams S.R., Buggy J.,
RA   Clark J.M.;
RT   "Identification of substrates of human protein-tyrosine phosphatase
RT   PTPN22.";
RL   J. Biol. Chem. 281:11002-11010(2006).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=17729039; DOI=10.1080/08916930701464897;
RA   Vang T., Miletic A.V., Bottini N., Mustelin T.;
RT   "Protein tyrosine phosphatase PTPN22 in human autoimmunity.";
RL   Autoimmunity 40:453-461(2007).
RN   [11]
RP   ALTERNATIVE SPLICING (ISOFORM 6).
RX   PubMed=22427951; DOI=10.1371/journal.pone.0033067;
RA   Chang H.H., Tai T.S., Lu B., Iannaccone C., Cernadas M., Weinblatt M.,
RA   Shadick N., Miaw S.C., Ho I.C.;
RT   "PTPN22.6, a dominant negative isoform of PTPN22 and potential
RT   biomarker of rheumatoid arthritis.";
RL   PLoS ONE 7:E33067-E33067(2012).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TRAF3.
RX   PubMed=23871208; DOI=10.1016/j.immuni.2013.06.013;
RA   Wang Y., Shaked I., Stanford S.M., Zhou W., Curtsinger J.M.,
RA   Mikulski Z., Shaheen Z.R., Cheng G., Sawatzke K., Campbell A.M.,
RA   Auger J.L., Bilgic H., Shoyama F.M., Schmeling D.O., Balfour H.H. Jr.,
RA   Hasegawa K., Chan A.C., Corbett J.A., Binstadt B.A., Mescher M.F.,
RA   Ley K., Bottini N., Peterson E.J.;
RT   "The autoimmunity-associated gene PTPN22 potentiates toll-like
RT   receptor-driven, type 1 interferon-dependent immunity.";
RL   Immunity 39:111-122(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-449, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   FUNCTION.
RX   PubMed=23991106; DOI=10.1371/journal.pone.0072384;
RA   Spalinger M.R., Lang S., Vavricka S.R., Fried M., Rogler G.,
RA   Scharl M.;
RT   "Protein tyrosine phosphatase non-receptor type 22 modulates NOD2-
RT   induced cytokine release and autophagy.";
RL   PLoS ONE 8:E72384-E72384(2013).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-294 IN COMPLEX WITH
RP   INHIBITOR, FUNCTION, PHOSPHORYLATION AT SER-35, AND MUTAGENESIS OF
RP   SER-35 AND THR-36.
RX   PubMed=18056643; DOI=10.1073/pnas.0706233104;
RA   Yu X., Sun J.P., He Y., Guo X., Liu S., Zhou B., Hudmon A.,
RA   Zhang Z.Y.;
RT   "Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-
RT   specific tyrosine phosphatase implicated in autoimmune diseases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:19767-19772(2007).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-302, DISULFIDE BOND, AND
RP   MUTAGENESIS OF CYS-129 AND CYS-231.
RX   PubMed=19371084; DOI=10.1021/bi900166y;
RA   Tsai S.J., Sen U., Zhao L., Greenleaf W.B., Dasgupta J., Fiorillo E.,
RA   Orru V., Bottini N., Chen X.S.;
RT   "Crystal structure of the human lymphoid tyrosine phosphatase
RT   catalytic domain: insights into redox regulation.";
RL   Biochemistry 48:4838-4845(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1-302, AND FUNCTION.
RX   PubMed=19167335; DOI=10.1016/j.cell.2008.11.038;
RA   Barr A.J., Ugochukwu E., Lee W.H., King O.N.F., Filippakopoulos P.,
RA   Alfano I., Savitsky P., Burgess-Brown N.A., Mueller S., Knapp S.;
RT   "Large-scale structural analysis of the classical human protein
RT   tyrosine phosphatome.";
RL   Cell 136:352-363(2009).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 2-309 OF WILD TYPE AND
RP   VARIANT GLN-263, VARIANT GLN-263, CATALYTIC ACTIVITY, AND
RP   CHARACTERIZATION OF VARIANT GLN-263.
RX   PubMed=18981062; DOI=10.1093/hmg/ddn363;
RA   Orru V., Tsai S.J., Rueda B., Fiorillo E., Stanford S.M., Dasgupta J.,
RA   Hartiala J., Zhao L., Ortego-Centeno N., D'Alfonso S., Arnett F.C.,
RA   Wu H., Gonzalez-Gay M.A., Tsao B.P., Pons-Estel B.,
RA   Alarcon-Riquelme M.E., He Y., Zhang Z.Y., Allayee H., Chen X.S.,
RA   Martin J., Bottini N., Danieli M.G., Galeazzi M., Sabbadini M.G.,
RA   Migliaresi S., Sebastiani G.D.;
RT   "A loss-of-function variant of PTPN22 is associated with reduced risk
RT   of systemic lupus erythematosus.";
RL   Hum. Mol. Genet. 18:569-579(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-310 IN COMPLEX WITH
RP   SUBSTRATE.
RA   Seidel R.D., Love J., Piserchio A., Cowburn D.;
RT   "Lyp/PTPN22 phosphatase domain: substrate recognition and specificity
RT   for Src family kinases.";
RL   Submitted (DEC-2009) to the PDB data bank.
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-294 OF MUTANT SER-227 ALONE
RP   AND IN COMPLEX WITH SKAP2 PEPTIDE, SUBSTRATE SPECIFICITY, AND
RP   FUNCTION.
RX   PubMed=21719704; DOI=10.1074/jbc.M111.254722;
RA   Yu X., Chen M., Zhang S., Yu Z.H., Sun J.P., Wang L., Liu S.,
RA   Imasaki T., Takagi Y., Zhang Z.Y.;
RT   "Substrate specificity of lymphoid-specific tyrosine phosphatase (Lyp)
RT   and identification of Src kinase-associated protein of 55 kDa homolog
RT   (SKAP-HOM) as a Lyp substrate.";
RL   J. Biol. Chem. 286:30526-30534(2011).
RN   [21]
RP   VARIANT RA TRP-620, INTERACTION WITH CSK, AND TISSUE SPECIFICITY.
RX   PubMed=15208781; DOI=10.1086/422827;
RA   Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J.,
RA   Chokkalingam A.P., Alexander H.C., Ardlie K.G., Huang Q., Smith A.M.,
RA   Spoerke J.M., Conn M.T., Chang M., Chang S.Y., Saiki R.K.,
RA   Catanese J.J., Leong D.U., Garcia V.E., McAllister L.B., Jeffery D.A.,
RA   Lee A.T., Batliwalla F., Remmers E., Criswell L.A., Seldin M.F.,
RA   Kastner D.L., Amos C.I., Sninsky J.J., Gregersen P.K.;
RT   "A missense single-nucleotide polymorphism in a gene encoding a
RT   protein tyrosine phosphatase (PTPN22) is associated with rheumatoid
RT   arthritis.";
RL   Am. J. Hum. Genet. 75:330-337(2004).
RN   [22]
RP   VARIANT SLE TRP-620.
RX   PubMed=15273934; DOI=10.1086/423790;
RA   Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S.,
RA   Carlton V.E.H., Chang M., Ramos P., Baechler E.C., Batliwalla F.M.,
RA   Novitzke J., Williams A.H., Gillett C., Rodine P., Graham R.R.,
RA   Ardlie K.G., Gaffney P.M., Moser K.L., Petri M., Begovich A.B.,
RA   Gregersen P.K., Behrens T.W.;
RT   "Genetic association of the R620W polymorphism of protein tyrosine
RT   phosphatase PTPN22 with human SLE.";
RL   Am. J. Hum. Genet. 75:504-507(2004).
RN   [23]
RP   VARIANT IDDM TRP-620, AND CHARACTERIZATION OF VARIANT IDDM TRP-620.
RX   PubMed=15004560; DOI=10.1038/ng1323;
RA   Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K.,
RA   Rostamkhani M., MacMurray J., Meloni G.F., Lucarelli P.,
RA   Pellecchia M., Eisenbarth G.S., Comings D., Mustelin T.;
RT   "A functional variant of lymphoid tyrosine phosphatase is associated
RT   with type I diabetes.";
RL   Nat. Genet. 36:337-338(2004).
RN   [24]
RP   INVOLVEMENT IN GRAVES DISEASE, INVOLVEMENT IN ADDISON DISEASE, AND
RP   VARIANT TRP-620.
RX   PubMed=15531553; DOI=10.1210/jc.2004-1108;
RA   Velaga M.R., Wilson V., Jennings C.E., Owen C.J., Herington S.,
RA   Donaldson P.T., Ball S.G., James R.A., Quinton R., Perros P.,
RA   Pearce S.H.;
RT   "The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase
RT   (LYP) gene is a major determinant of Graves' disease.";
RL   J. Clin. Endocrinol. Metab. 89:5862-5865(2004).
RN   [25]
RP   INVOLVEMENT IN HASHIMOTO THYROIDITIS, AND VARIANT TRP-620.
RX   PubMed=15719322; DOI=10.1086/429096;
RA   Criswell L.A., Pfeiffer K.A., Lum R.F., Gonzales B., Novitzke J.,
RA   Kern M., Moser K.L., Begovich A.B., Carlton V.E., Li W., Lee A.T.,
RA   Ortmann W., Behrens T.W., Gregersen P.K.;
RT   "Analysis of families in the multiple autoimmune disease genetics
RT   consortium (MADGC) collection: the PTPN22 620W allele associates with
RT   multiple autoimmune phenotypes.";
RL   Am. J. Hum. Genet. 76:561-571(2005).
RN   [26]
RP   VARIANT VTLG TRP-620.
RX   PubMed=16015369; DOI=10.1038/sj.gene.6364243;
RA   Canton I., Akhtar S., Gavalas N.G., Gawkrodger D.J., Blomhoff A.,
RA   Watson P.F., Weetman A.P., Kemp E.H.;
RT   "A single-nucleotide polymorphism in the gene encoding lymphoid
RT   protein tyrosine phosphatase (PTPN22) confers susceptibility to
RT   generalised vitiligo.";
RL   Genes Immun. 6:584-587(2005).
RN   [27]
RP   VARIANT TRP-620, AND CHARACTERIZATION OF VARIANT TRP-620.
RX   PubMed=19265110; DOI=10.4049/jimmunol.0713370;
RA   Arechiga A.F., Habib T., He Y., Zhang X., Zhang Z.Y., Funk A.,
RA   Buckner J.H.;
RT   "Cutting edge: the PTPN22 allelic variant associated with autoimmunity
RT   impairs B cell signaling.";
RL   J. Immunol. 182:3343-3347(2009).
RN   [28]
RP   VARIANTS GLN-263 AND TRP-620, AND CHARACTERIZATION OF VARIANTS GLN-263
RP   AND TRP-620.
RX   PubMed=21287672; DOI=10.1002/ibd.21630;
RA   Diaz-Gallo L.M., Espino-Paisan L., Fransen K., Gomez-Garcia M.,
RA   van Sommeren S., Cardena C., Rodrigo L., Mendoza J.L., Taxonera C.,
RA   Nieto A., Alcain G., Cueto I., Lopez-Nevot M.A., Bottini N.,
RA   Barclay M.L., Crusius J.B., van Bodegraven A.A., Wijmenga C.,
RA   Ponsioen C.Y., Gearry R.B., Roberts R.L., Weersma R.K., Urcelay E.,
RA   Merriman T.R., Alizadeh B.Z., Martin J.;
RT   "Differential association of two PTPN22 coding variants with Crohn's
RT   disease and ulcerative colitis.";
RL   Inflamm. Bowel Dis. 17:2287-2294(2011).
RN   [29]
RP   VARIANTS PHE-201; GLN-263 AND TRP-266, AND CHARACTERIZATION OF
RP   VARIANTS PHE-201; GLN-263 AND TRP-266.
RX   PubMed=22952725; DOI=10.1371/journal.pone.0043631;
RA   Liu J., Chen M., Li R., Yang F., Shi X., Zhu L., Wang H.M., Yao W.,
RA   Liu Q., Meng F.G., Sun J.P., Pang Q., Yu X.;
RT   "Biochemical and functional studies of lymphoid-specific tyrosine
RT   phosphatase (Lyp) variants S201F and R266W.";
RL   PLoS ONE 7:E43631-E43631(2012).
CC   -!- FUNCTION: Acts as negative regulator of T-cell receptor (TCR)
CC       signaling by direct dephosphorylation of the Src family kinases
CC       LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV,
CC       VCP and other key signaling molecules (PubMed:16461343,
CC       PubMed:18056643). Associates with and probably dephosphorylates
CC       CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue
CC       (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-
CC       493' residue (PubMed:16461343). Dephosphorylates the immune system
CC       activator SKAP2 (PubMed:21719704). Positively regulates toll-like
CC       receptor (TLR)-induced type 1 interferon production
CC       (PubMed:23871208). Promotes host antiviral responses mediated by
CC       type 1 interferon (By similarity). Regulates NOD2-induced pro-
CC       inflammatory cytokine secretion and autophagy (PubMed:23991106).
CC       {ECO:0000250|UniProtKB:P29352, ECO:0000269|PubMed:16461343,
CC       ECO:0000269|PubMed:18056643, ECO:0000269|PubMed:19167335,
CC       ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:23871208,
CC       ECO:0000269|PubMed:23991106}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044,
CC       ECO:0000269|PubMed:21719704}.
CC   -!- ENZYME REGULATION: Down-regulated by phosphorylation.
CC   -!- SUBUNIT: Interacts with CSK (PubMed:15208781). Interacts with LPXN
CC       (By similarity). Interacts with CBL (PubMed:10068674). Interacts
CC       with TRAF3 (via MATH domain); the interaction promotes TRAF3
CC       polyubiquitination (PubMed:23871208).
CC       {ECO:0000250|UniProtKB:P29352, ECO:0000269|PubMed:10068674,
CC       ECO:0000269|PubMed:15208781, ECO:0000269|PubMed:18056643,
CC       ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:23871208,
CC       ECO:0000269|Ref.19}.
CC   -!- INTERACTION:
CC       P20963:CD247; NbExp=4; IntAct=EBI-1211241, EBI-1165705;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-1211241, EBI-297353;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-1211241, EBI-401755;
CC       P06239:LCK; NbExp=6; IntAct=EBI-1211241, EBI-1348;
CC       O43586:PSTPIP1; NbExp=6; IntAct=EBI-1211241, EBI-1050964;
CC       O75563:SKAP2; NbExp=3; IntAct=EBI-1211241, EBI-2483161;
CC       Q3UND0:Skap2 (xeno); NbExp=2; IntAct=EBI-1211241, EBI-642769;
CC       Q13114:TRAF3; NbExp=2; IntAct=EBI-1211241, EBI-357631;
CC       Q60803:Traf3 (xeno); NbExp=5; IntAct=EBI-1211241, EBI-520135;
CC       P43403:ZAP70; NbExp=4; IntAct=EBI-1211241, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=LyP1;
CC         IsoId=Q9Y2R2-1; Sequence=Displayed;
CC       Name=2; Synonyms=LyP2;
CC         IsoId=Q9Y2R2-2; Sequence=VSP_005134;
CC         Note=Due to intron retention.;
CC       Name=3;
CC         IsoId=Q9Y2R2-3; Sequence=VSP_039728;
CC         Note=No experimental confirmation available.;
CC       Name=4; Synonyms=LYP3;
CC         IsoId=Q9Y2R2-4; Sequence=VSP_039729;
CC       Name=5;
CC         IsoId=Q9Y2R2-5; Sequence=VSP_039725, VSP_039726, VSP_039727;
CC         Note=No experimental confirmation available.;
CC       Name=6; Synonyms=PTPN22.6;
CC         IsoId=Q9Y2R2-6; Sequence=VSP_044428, VSP_044429;
CC         Note=Lacks most of the phosphatase domain and functions as a
CC         dominant negative isoform of the full length PTPN22.;
CC   -!- TISSUE SPECIFICITY: Expressed in bone marrow, B and T-cells,
CC       PBMCs, natural killer cells, monocytes, dendritic cells and
CC       neutrophils (PubMed:15208781). Both isoform 1 and 4 are
CC       predominantly expressed in lymphoid tissues and cells. Isoform 1
CC       is expressed in thymocytes and both mature B and T-cells.
CC       {ECO:0000269|PubMed:15208781}.
CC   -!- INDUCTION: By muramyl-dipeptide and lipopolysaccharide.
CC       {ECO:0000269|PubMed:23991106}.
CC   -!- PTM: Phosphorylation on Ser-35 by PKC/PRKCD abrogates its ability
CC       to dephosphorylate and inactivate the SRC family kinases.
CC       {ECO:0000269|PubMed:18056643}.
CC   -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A
CC       chronic, relapsing, inflammatory, and often febrile multisystemic
CC       disorder of connective tissue, characterized principally by
CC       involvement of the skin, joints, kidneys and serosal membranes. It
CC       is of unknown etiology, but is thought to represent a failure of
CC       the regulatory mechanisms of the autoimmune system. The disease is
CC       marked by a wide range of system dysfunctions, an elevated
CC       erythrocyte sedimentation rate, and the formation of LE cells in
CC       the blood or bone marrow. {ECO:0000269|PubMed:15273934}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, insulin-dependent (IDDM) [MIM:222100]:
CC       A multifactorial disorder of glucose homeostasis that is
CC       characterized by susceptibility to ketoacidosis in the absence of
CC       insulin therapy. Clinical features are polydipsia, polyphagia and
CC       polyuria which result from hyperglycemia-induced osmotic diuresis
CC       and secondary thirst. These derangements result in long-term
CC       complications that affect the eyes, kidneys, nerves, and blood
CC       vessels. {ECO:0000269|PubMed:15004560}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory
CC       disease with autoimmune features and a complex genetic component.
CC       It primarily affects the joints and is characterized by
CC       inflammatory changes in the synovial membranes and articular
CC       structures, widespread fibrinoid degeneration of the collagen
CC       fibers in mesenchymal tissues, and by atrophy and rarefaction of
CC       bony structures. {ECO:0000269|PubMed:15208781}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Vitiligo (VTLG) [MIM:193200]: A pigmentary disorder of
CC       the skin and mucous membranes. It is characterized by
CC       circumscribed depigmented macules and patches, commonly on
CC       extensor aspects of extremities, on the face or neck and in skin
CC       folds. Vitiligo is a progressive disorder in which some or all of
CC       the melanocytes in the affected skin are selectively destroyed. It
CC       is a multifactorial disorder with a complex etiology probably
CC       including autoimmune mechanisms, and is associated with an
CC       elevated risk of other autoimmune diseases.
CC       {ECO:0000269|PubMed:16015369}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class 4 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF001846; AAD00904.1; -; mRNA.
DR   EMBL; AF001847; AAD00905.1; -; mRNA.
DR   EMBL; GU479452; ADD59979.1; -; mRNA.
DR   EMBL; AF077031; AAD27764.1; -; mRNA.
DR   EMBL; AK310570; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; EF064714; ABK41897.1; -; Genomic_DNA.
DR   EMBL; AL137856; CAI19068.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56575.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56576.1; -; Genomic_DNA.
DR   EMBL; BC017785; AAH17785.1; -; mRNA.
DR   EMBL; BC071670; AAH71670.1; -; mRNA.
DR   CCDS; CCDS863.1; -. [Q9Y2R2-1]
DR   CCDS; CCDS864.2; -. [Q9Y2R2-3]
DR   RefSeq; NP_001180360.1; NM_001193431.2. [Q9Y2R2-4]
DR   RefSeq; NP_001295226.1; NM_001308297.1.
DR   RefSeq; NP_036543.4; NM_012411.5. [Q9Y2R2-3]
DR   RefSeq; NP_057051.3; NM_015967.6. [Q9Y2R2-1]
DR   UniGene; Hs.535276; -.
DR   PDB; 2P6X; X-ray; 1.90 A; A/B=1-302.
DR   PDB; 2QCJ; X-ray; 3.00 A; A/B=1-294.
DR   PDB; 2QCT; X-ray; 2.80 A; A/B=1-294.
DR   PDB; 3BRH; X-ray; 2.20 A; A/B=1-310.
DR   PDB; 3H2X; X-ray; 2.20 A; A=1-302.
DR   PDB; 3OLR; X-ray; 2.50 A; A/B/C/D=1-294.
DR   PDB; 3OMH; X-ray; 2.90 A; A/B/C/D=1-294.
DR   PDB; 4J51; X-ray; 2.30 A; A/B=1-303.
DR   PDBsum; 2P6X; -.
DR   PDBsum; 2QCJ; -.
DR   PDBsum; 2QCT; -.
DR   PDBsum; 3BRH; -.
DR   PDBsum; 3H2X; -.
DR   PDBsum; 3OLR; -.
DR   PDBsum; 3OMH; -.
DR   PDBsum; 4J51; -.
DR   ProteinModelPortal; Q9Y2R2; -.
DR   SMR; Q9Y2R2; -.
DR   BioGrid; 117604; 14.
DR   DIP; DIP-29953N; -.
DR   IntAct; Q9Y2R2; 23.
DR   STRING; 9606.ENSP00000352833; -.
DR   BindingDB; Q9Y2R2; -.
DR   ChEMBL; CHEMBL2889; -.
DR   DEPOD; Q9Y2R2; -.
DR   iPTMnet; Q9Y2R2; -.
DR   PhosphoSitePlus; Q9Y2R2; -.
DR   BioMuta; PTPN22; -.
DR   DMDM; 20139861; -.
DR   PaxDb; Q9Y2R2; -.
DR   PeptideAtlas; Q9Y2R2; -.
DR   PRIDE; Q9Y2R2; -.
DR   DNASU; 26191; -.
DR   Ensembl; ENST00000460620; ENSP00000433141; ENSG00000134242. [Q9Y2R2-5]
DR   GeneID; 26191; -.
DR   KEGG; hsa:26191; -.
DR   UCSC; uc001edt.4; human. [Q9Y2R2-1]
DR   CTD; 26191; -.
DR   DisGeNET; 26191; -.
DR   GeneCards; PTPN22; -.
DR   HGNC; HGNC:9652; PTPN22.
DR   HPA; CAB012209; -.
DR   HPA; HPA004912; -.
DR   HPA; HPA013350; -.
DR   MalaCards; PTPN22; -.
DR   MIM; 152700; phenotype.
DR   MIM; 180300; phenotype.
DR   MIM; 193200; phenotype.
DR   MIM; 222100; phenotype.
DR   MIM; 600716; gene.
DR   neXtProt; NX_Q9Y2R2; -.
DR   OpenTargets; ENSG00000134242; -.
DR   Orphanet; 397; Giant cell arteritis.
DR   Orphanet; 900; Granulomatosis with polyangiitis.
DR   Orphanet; 85408; Juvenile rheumatoid factor-negative polyarthritis.
DR   Orphanet; 85410; Oligoarticular juvenile arthritis.
DR   Orphanet; 93552; Pediatric systemic lupus erythematosus.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   Orphanet; 3437; Vogt-Koyanagi-Harada disease.
DR   PharmGKB; PA33995; -.
DR   eggNOG; KOG0789; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136380; -.
DR   HOVERGEN; HBG103877; -.
DR   InParanoid; Q9Y2R2; -.
DR   KO; K18024; -.
DR   PhylomeDB; Q9Y2R2; -.
DR   TreeFam; TF351977; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   SignaLink; Q9Y2R2; -.
DR   SIGNOR; Q9Y2R2; -.
DR   ChiTaRS; PTPN22; human.
DR   EvolutionaryTrace; Q9Y2R2; -.
DR   GeneWiki; PTPN22; -.
DR   GenomeRNAi; 26191; -.
DR   PRO; PR:Q9Y2R2; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000134242; -.
DR   CleanEx; HS_PTPN22; -.
DR   ExpressionAtlas; Q9Y2R2; baseline and differential.
DR   Genevisible; Q9Y2R2; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0019900; F:kinase binding; ISS:BHF-UCL.
DR   GO; GO:0016791; F:phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; ISS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IDA:UniProtKB.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1900165; P:negative regulation of interleukin-6 secretion; IMP:UniProtKB.
DR   GO; GO:2000483; P:negative regulation of interleukin-8 secretion; IMP:UniProtKB.
DR   GO; GO:0043508; P:negative regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0070433; P:negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903753; P:negative regulation of p38MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0050868; P:negative regulation of T cell activation; IMP:BHF-UCL.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IMP:UniProtKB.
DR   GO; GO:0035644; P:phosphoanandamide dephosphorylation; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1902715; P:positive regulation of interferon-gamma secretion; IMP:UniProtKB.
DR   GO; GO:1902523; P:positive regulation of protein K63-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; IMP:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0045088; P:regulation of innate immune response; IC:BHF-UCL.
DR   GO; GO:0032817; P:regulation of natural killer cell proliferation; IDA:BHF-UCL.
DR   GO; GO:1901222; P:regulation of NIK/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IMP:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR016276; PTPN22.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000930; PTPN8_PTPN22; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autophagy; Complete proteome;
KW   Cytoplasm; Diabetes mellitus; Disease mutation; Disulfide bond;
KW   Hydrolase; Immunity; Phosphoprotein; Polymorphism;
KW   Protein phosphatase; Reference proteome; Systemic lupus erythematosus.
FT   CHAIN         1    807       Tyrosine-protein phosphatase non-receptor
FT                                type 22.
FT                                /FTId=PRO_0000094775.
FT   DOMAIN       24    289       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      227    233       Substrate binding.
FT   ACT_SITE    227    227       Phosphocysteine intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160,
FT                                ECO:0000255|PROSITE-ProRule:PRU10044}.
FT   BINDING     195    195       Substrate. {ECO:0000250}.
FT   BINDING     274    274       Substrate. {ECO:0000269|Ref.19}.
FT   MOD_RES      35     35       Phosphoserine; by PKC/PRKCD.
FT                                {ECO:0000269|PubMed:18056643}.
FT   MOD_RES     449    449       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     635    635       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P29352}.
FT   MOD_RES     684    684       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P29352}.
FT   MOD_RES     692    692       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P29352}.
FT   DISULFID    129    227       {ECO:0000269|PubMed:19371084}.
FT   VAR_SEQ     124    250       Missing (in isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044428.
FT   VAR_SEQ     137    160       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039725.
FT   VAR_SEQ     181    203       ETRTIYQFHYKNWPDHDVPSSID -> VSVILAHQTSLQNL
FT                                FSQITPAHF (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039726.
FT   VAR_SEQ     204    807       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039727.
FT   VAR_SEQ     251    305       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039728.
FT   VAR_SEQ     647    674       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:21044313}.
FT                                /FTId=VSP_039729.
FT   VAR_SEQ     685    807       ELHQDRSSPPPPLPERTLESFFLADEDCMQAQSIETYSTSY
FT                                PDTMENSTSSKQTLKTPGKSFTRSKSLKILRNMKKSICNSC
FT                                PPNKPAESVQSNNSSSFLNFGFANRFSKPKGPRNPPPTWNI
FT                                -> GKNFSWL (in isoform 2).
FT                                {ECO:0000303|PubMed:10068674}.
FT                                /FTId=VSP_005134.
FT   VAR_SEQ     788    807       FANRFSKPKGPRNPPPTWNI -> MCVILLKS (in
FT                                isoform 6).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044429.
FT   VARIANT     201    201       S -> F (polymorphism; moderately reduces
FT                                phosphatase activity; dbSNP:rs7416347).
FT                                {ECO:0000269|PubMed:22952725}.
FT                                /FTId=VAR_072629.
FT   VARIANT     263    263       R -> Q (polymorphism; reduces risk of SLE
FT                                and RA but not IDDM; associated with
FT                                reduced risk of ulcerative colitis but
FT                                not of Crohn disease; severely reduces
FT                                phosphatase activity; dbSNP:rs33996649).
FT                                {ECO:0000269|PubMed:18981062,
FT                                ECO:0000269|PubMed:21287672,
FT                                ECO:0000269|PubMed:22952725}.
FT                                /FTId=VAR_072630.
FT   VARIANT     266    266       R -> W (polymorphism; severely reduces
FT                                phosphatase activity; dbSNP:rs72650670).
FT                                {ECO:0000269|PubMed:22952725}.
FT                                /FTId=VAR_072631.
FT   VARIANT     620    620       R -> W (in IDDM, RA, SLE and VTLG; also
FT                                found in patients with Graves disease,
FT                                Hashimoto thyroiditis and Addison
FT                                disease; associated with reduced risk of
FT                                Crohn disease but not of ulcerative
FT                                colitis; affects CSK kinase binding;
FT                                alters B cell receptor signaling and
FT                                memory B cell proliferation;
FT                                dbSNP:rs2476601).
FT                                {ECO:0000269|PubMed:15004560,
FT                                ECO:0000269|PubMed:15208781,
FT                                ECO:0000269|PubMed:15273934,
FT                                ECO:0000269|PubMed:15531553,
FT                                ECO:0000269|PubMed:15719322,
FT                                ECO:0000269|PubMed:16015369,
FT                                ECO:0000269|PubMed:16710414,
FT                                ECO:0000269|PubMed:19265110,
FT                                ECO:0000269|PubMed:21044313,
FT                                ECO:0000269|PubMed:21287672,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022605.
FT   MUTAGEN      35     35       S->E: Loss of phosphorylation by
FT                                PKC/PRKCD. {ECO:0000269|PubMed:18056643}.
FT   MUTAGEN      36     36       T->E: No effect on phosphorylation by
FT                                PKC/PRKCD. {ECO:0000269|PubMed:18056643}.
FT   MUTAGEN     129    129       C->S: Decreases activity 2 fold.
FT                                {ECO:0000269|PubMed:19371084}.
FT   MUTAGEN     231    231       C->S: Decreases activity 7 fold.
FT                                {ECO:0000269|PubMed:19371084}.
FT   CONFLICT     51     52       KP -> NA (in Ref. 1; AAD00904/AAD00905).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       V -> G (in Ref. 2; AAD27764).
FT                                {ECO:0000305}.
FT   CONFLICT    147    147       G -> V (in Ref. 2; AAD27764).
FT                                {ECO:0000305}.
FT   CONFLICT    240    240       I -> IV (in Ref. 1; AAD00905).
FT                                {ECO:0000305}.
FT   CONFLICT    372    372       A -> V (in Ref. 4; AK310570).
FT                                {ECO:0000305}.
FT   CONFLICT    420    420       L -> P (in Ref. 2; AAD27764).
FT                                {ECO:0000305}.
FT   CONFLICT    742    742       P -> S (in Ref. 2; AAD27764).
FT                                {ECO:0000305}.
FT   HELIX         3     16       {ECO:0000244|PDB:2P6X}.
FT   HELIX        21     40       {ECO:0000244|PDB:2P6X}.
FT   HELIX        47     50       {ECO:0000244|PDB:2P6X}.
FT   HELIX        52     55       {ECO:0000244|PDB:2P6X}.
FT   STRAND       59     62       {ECO:0000244|PDB:3OMH}.
FT   HELIX        67     69       {ECO:0000244|PDB:2P6X}.
FT   STRAND       70     72       {ECO:0000244|PDB:4J51}.
FT   TURN         80     83       {ECO:0000244|PDB:4J51}.
FT   STRAND       86     92       {ECO:0000244|PDB:2P6X}.
FT   STRAND       95    102       {ECO:0000244|PDB:2P6X}.
FT   HELIX       107    109       {ECO:0000244|PDB:2P6X}.
FT   HELIX       110    119       {ECO:0000244|PDB:2P6X}.
FT   STRAND      124    127       {ECO:0000244|PDB:2P6X}.
FT   STRAND      131    133       {ECO:0000244|PDB:2P6X}.
FT   STRAND      135    137       {ECO:0000244|PDB:3BRH}.
FT   STRAND      146    148       {ECO:0000244|PDB:2QCJ}.
FT   STRAND      151    153       {ECO:0000244|PDB:2P6X}.
FT   STRAND      156    165       {ECO:0000244|PDB:2P6X}.
FT   STRAND      167    178       {ECO:0000244|PDB:2P6X}.
FT   STRAND      181    190       {ECO:0000244|PDB:2P6X}.
FT   STRAND      195    197       {ECO:0000244|PDB:2QCJ}.
FT   HELIX       199    202       {ECO:0000244|PDB:2P6X}.
FT   HELIX       203    215       {ECO:0000244|PDB:2P6X}.
FT   STRAND      218    221       {ECO:0000244|PDB:3BRH}.
FT   STRAND      223    226       {ECO:0000244|PDB:2P6X}.
FT   STRAND      228    232       {ECO:0000244|PDB:2P6X}.
FT   HELIX       233    248       {ECO:0000244|PDB:2P6X}.
FT   HELIX       258    266       {ECO:0000244|PDB:2P6X}.
FT   HELIX       276    301       {ECO:0000244|PDB:2P6X}.
SQ   SEQUENCE   807 AA;  91705 MW;  1ABE8AE89C9D9FBF CRC64;
     MDQREILQKF LDEAQSKKIT KEEFANEFLK LKRQSTKYKA DKTYPTTVAE KPKNIKKNRY
     KDILPYDYSR VELSLITSDE DSSYINANFI KGVYGPKAYI ATQGPLSTTL LDFWRMIWEY
     SVLIIVMACM EYEMGKKKCE RYWAEPGEMQ LEFGPFSVSC EAEKRKSDYI IRTLKVKFNS
     ETRTIYQFHY KNWPDHDVPS SIDPILELIW DVRCYQEDDS VPICIHCSAG CGRTGVICAI
     DYTWMLLKDG IIPENFSVFS LIREMRTQRP SLVQTQEQYE LVYNAVLELF KRQMDVIRDK
     HSGTESQAKH CIPEKNHTLQ ADSYSPNLPK STTKAAKMMN QQRTKMEIKE SSSFDFRTSE
     ISAKEELVLH PAKSSTSFDF LELNYSFDKN ADTTMKWQTK AFPIVGEPLQ KHQSLDLGSL
     LFEGCSNSKP VNAAGRYFNS KVPITRTKST PFELIQQRET KEVDSKENFS YLESQPHDSC
     FVEMQAQKVM HVSSAELNYS LPYDSKHQIR NASNVKHHDS SALGVYSYIP LVENPYFSSW
     PPSGTSSKMS LDLPEKQDGT VFPSSLLPTS STSLFSYYNS HDSLSLNSPT NISSLLNQES
     AVLATAPRID DEIPPPLPVR TPESFIVVEE AGEFSPNVPK SLSSAVKVKI GTSLEWGGTS
     EPKKFDDSVI LRPSKSVKLR SPKSELHQDR SSPPPPLPER TLESFFLADE DCMQAQSIET
     YSTSYPDTME NSTSSKQTLK TPGKSFTRSK SLKILRNMKK SICNSCPPNK PAESVQSNNS
     SSFLNFGFAN RFSKPKGPRN PPPTWNI
//
